Ulcerative colitis symptom tracker

    Help your doctor understand your symptoms

    Print out this 7-day symptom tracker to help you monitor and document your ulcerative colitis (UC) symptoms from one week to the next—in good times and bad. In fact, print one out every week. Really pay attention to your symptoms and how they make you feel.

    The week-in-review section of the symptom tracker is helpful in summarizing what you noticed during a particular week and may help you and your doctor understand your condition in a new way. Be sure to share your findings with your doctor at your next visit.

    * 
    • This APRISO Instant Savings Card is only valid for patients 18 years of age or older with commercial insurance, including commercially insured patients without coverage for APRISO. Patients without commercial insurance are not eligible. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, or the Puerto Rico Government Health Insurance Plan. Eligible insured patients with coverage for APRISO pay a $0 co-pay for their initial prescription, and eligible insured patients without coverage for APRISO pay a $0 out-of-pocket expense. Salix Pharmaceuticals will pay the remaining co-pay/out-of-pocket expense up to the maximum amount of $110 for the first fill. For each subsequent use, the patient pays the initial $10, with a maximum benefit of $100. Maximum benefits apply. Maximum benefits are as follows: initial prescription/$110, for 1 use total for a calendar year, and for each subsequent prescription/$100, for 1 use per month for a calendar year. Salix Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time without notice.

    INDICATION

    APRISO® (mesalamine) extended-release capsules are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.

    IMPORTANT SAFETY INFORMATION—APRISO extended-release capsules

    • You should not take APRISO extended-release capsules if you experience an allergic reaction to salicylates or aminosalicylates, or to any of the components of APRISO capsules.

    • Kidney impairment has been reported in patients given products like APRISO (contain mesalamine or are converted to mesalamine). It is recommended that you have an evaluation of kidney function prior to treatment with APRISO therapy and periodically while on therapy. Talk to your doctor if you have any kidney problems before taking APRISO.

    • Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of your ulcerative colitis. Symptoms include cramping, acute abdominal (stomach) pain and bloody diarrhea, sometimes fever, headache, and rash. Talk to your doctor if you experience a worsening of these problems after you start treatment.

    • If you have liver disease, talk to your doctor before taking APRISO. There have been reports of liver failure in patients with liver disease who have taken mesalamine.

    • In the clinical studies, the most common side effects occurring in at least 3% of patients taking APRISO were headache, diarrhea, upper abdominal (stomach) pain, nausea, nasopharyngitis (inflammation of the nasal passages), flu and flu-like illness, and inflammation of the sinuses.

    • You should not take APRISO while taking antacids because the dissolving of APRISO granules depends on the acidity in your stomach.

    • If you are 65 years old or older, talk to your doctor before taking APRISO. Blood cell count must be monitored closely if you are 65 or older and on mesalamine therapy.

    • If you have phenylketonuria (PKU), please be aware that each APRISO capsule contains aspartame equivalent to 0.56 mg of phenylalanine, so that the recommended adult dosing provides an equivalent of 2.24 mg of phenylalanine per day.


    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.


    For product information, adverse event reports, and product complaint reports, please contact:
    Salix Product Information Call Center
    Phone: 1-800-508-0024
    Fax: 1-510-595-8183
    Email: salixmc@dlss.com

    Please click here for full Prescribing Information for APRISO extended-release capsules.